Teva Pharma (TEVA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
- Exclusive-China's DeepSeek developing its own AI chip, sources say
Leerink Partners Remains Bullish as Teva Pharma (TEVA) Awaits IPR Ruling
August 15, 2016 2:00 PM EDTLeerink Partners reiterated an Outperform rating and $66.00 price target on Teva Pharma (NYSE: TEVA) ahead of an IPR ruling on three TEVA patents.
Analyst Jason Gerberry commented, "We continue to eagerly await the IPR (inter partes review) ruling on three TEVA patents that cover... More
Guggenheim Reiterates Buy on Teva Pharma (TEVA) Following AGN Deal
August 15, 2016 7:21 AM EDTGuggenheim reiterated a Buy rating and $80.00 price target on Teva Pharma (NYSE: TEVA) following the close of the company's AGN generics deal earlier this month. Later this month, TEVA will receive two decisions on the IPR challenge for Copaxone 40mg, about whether three patents have been invalidated and if a fourth will be considered for IPR.
Analyst Louise Chen commented, "After closing the AGN generics deal... More
